Markets
In this photo illustration, the Hims & Hers Health logo is...
(Thomas Fuller/Getty Images)

Hims & Hers to sell Eli Lilly’s Zepbound on its platform

Hims & Hers is unable to sell copies of GLP-1 agonists after the FDA declared the shortage of those drugs is over.

J. Edward Moreno
4/1/25 1:16PM

Hims & Hers shares rose Tuesday afternoon after the telehealth company said it would offer Eli Lilly’s blockbuster weight-loss drug Zepbound on its platform.

The move gives Hims & Hers a way to offer its users the cutting edge of popular weight-loss drugs after the FDA severely limited Hims’ ability to produce them itself. On February 21, the Food and Drug Administration announced an end to the shortage of semaglutide, the active ingredient in Ozempic and Wegovy, drugs made by Novo Nordisk. Hims & Hers made about $230 million selling compounded semaglutide in 2024. The company has never sold compounded tirzepatide, the active ingredient in Zepbound.

Hims & Hers users can now get a prescription for Zepbound on the platform, but not at a discount: it costs about $1,899 a month, according to the company’s website. Sometimes insured customers can be reimbursed for the drug. For comparison, Lilly offers Zepbound to uninsured patients for about $500 a month, and compounded semaglutide costs about $200 a month.

Shares initially jumped sharply on the news, but gains faded in the afternoon as investors parsed the news.

Hims & Hers share price tanked after the FDA announcement on February 21, as it became unclear to what extent the company could continue making money selling GLP-1 drugs. Even with the recent boost, which faded hours later, Hims & Hers is still significantly down since the FDA called off the shortage.

The company has previously said that it would sell generics of Novos older weight-loss drugs and personalized doses of semaglutide. We’re committed to bringing our customers more treatment options that best suit their needs, and we’ve now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform, the company said in its announcement.

Lilly has struck deals to sell discounted vials of Zepbound on Ro, a privately held Hims & Hers competitor, and Amazon Pharmacy. Novo has launched its own direct-to-consumer platform to sell discounted Wegovy to patients without insurance.

More Markets

See all Markets
markets

US stocks swiftly pare gains as White House confirms 104% tariffs on China

US stocks are falling out of bed, with the S&P 500 paring an advance of more than 3% down to about 0.5% on confirmation that an escalating trade war is indeed happening.

White House press secretary Karoline Leavitt said the additional 50% tariffs imposed on China following its retaliatory tariffs on the US are going into effect.

Here’s this headline, which is definitely real:

*LEAVITT: US TO IMPOSE 104% TARIFFS ON CHINA TOMORROW: FOX BIZ

A Goldman Sachs basket of US stocks with high exposure to China (ex semiconductors) is in the red and lagging the benchmark US stock index, with the underperformance swelling after that headline hit the wires.

One lesson from Monday’s mayhem — and a factor behind Tuesday’s early gains — is that traders are desperately looking for, and believing in, potential off-ramps from highly disruptive trade levies. The recent price action may serve as a portent of what awaits if the current policy course we’re on stays intact.

markets

BofA: Cigarettes and Coca-Cola tend to hold up during recessions

If the US does spiral into a self-induced recession, as economists are increasingly predicting, history shows consumer staples may be one of the safest places to invest, according to Bank of America analysts.

Some of the companies it recommends are Zyn maker Philip Morris International, sugary drink staple Coca-Cola, and condiment and spice seller McCormick. Those industries have outperformed in most recessions, with the exception of COVID-19.

They have also outperformed this year as President Trump’s tariff threats have rattled global markets.

Screenshot 2025-04-08 at 12.22.37 PM
(Bank of America)
Screenshot 2025-04-08 at 12.23.08 PM
(Bank of America)
Levi's storefront

Levi’s says tariffs will have minimal impact on margins this quarter

The denim giant also topped Q1 earnings estimates thanks to a campaign-fueled demand boost.

markets

Investors have a “particularly enhanced buying opportunity” in Apple, says Bank of America

Bank of America is pounding the table on Apple’s attractive risk-reward profile after the stock’s massive tariff-induced plunge.

“In our view, the pullback presents a particularly enhanced buying opportunity for investors to own a high-quality name,” a team led by Wamsi Mohan wrote.

While acknowledging that “history is not a guide,” Mohan examined times when the iPhone maker’s 12-month forward price-to-earnings ratio has fallen below 25x, a threshold it breached recently.

The forward returns are encouraging:

Apple forward performance
Source: BofA

Bank of America has a “buy” rating and $250 price target on the shares.

Management has some options at its disposal to blunt the potential impact of tariffs, according to Mohan, such as moving production to India, raising selling prices, or squeezing its suppliers.

Taken plainly, this note is a resounding endorsement of one of America’s leading companies. But I think it’s also revealing as to the challenges investors have in trying to assess what constitutes “value” in the current market environment.

First, a forward price-to-earnings ratio below 25x doesn’t exactly scream “cheap.” Second, all these periods of multiple compression examined by BofA have come since the end of 2020. So, we’re really only looking at a valuation cushion that’s seemingly existed for the company during a time in which the US stock market as a whole has been very richly valued. The sample size is understandably small, and I have thoughts about the folly of low-n analysis.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.